Article (Scientific journals)
Beyond corticosteroids: future prospects in the management of inflammation in COPD.
Roche, N.; Marthan, R.; Berger, P. et al.
2011In European Respiratory Review, 20 (121), p. 175-82
Peer Reviewed verified by ORBi
 

Files


Full Text
Beyond corticosteroid_future prospects in the management of inflammation in COPD_Roche_11_EurRepirRev.pdf
Publisher postprint (401.26 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adrenal Cortex Hormones/therapeutic use; Anti-Inflammatory Agents/therapeutic use; Humans; Lung/drug effects/immunology/physiopathology; Phenotype; Phosphodiesterase 4 Inhibitors/therapeutic use; Pulmonary Disease, Chronic Obstructive/drug therapy/immunology/physiopathology; Treatment Outcome
Abstract :
[en] Inflammation plays a central role in the pathophysiology of chronic obstructive pulmonary disease (COPD). Exposure to cigarette smoke induces the recruitment of inflammatory cells in the airways and stimulates innate and adaptive immune mechanisms. Airway inflammation is involved in increased bronchial wall thickness, increased bronchial smooth muscle tone, mucus hypersecretion and loss of parenchymal elastic structures. Oxidative stress impairs tissue integrity, accelerates lung ageing and reduces the efficacy of corticosteroids by decreasing levels of histone deacetylase-2. Protease-antiprotease imbalance impairs tissues and is involved in inflammatory processes. Inflammation is also present in the pulmonary artery wall and at the systemic level in COPD patients, and may be involved in COPD-associated comorbidities. Proximal airways inflammation contributes to symptoms of chronic bronchitis while distal and parenchymal inflammation relates to airflow obstruction, emphysema and hyperinflation. Basal levels of airways and systemic inflammation are increased in frequent exacerbators. Inhaled corticosteroids are much less effective in COPD than in asthma, which relates to the intrinsically poor reversibility of COPD-related airflow obstruction and to molecular mechanisms of resistance relating to oxidative stress. Ongoing research aims at developing new drugs targeting more intimately COPD-specific mechanisms of inflammation, hypersecretion and tissue destruction and repair. Among new anti-inflammatory agents, phosphodiesterase-4 inhibitors have been the first to emerge.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Roche, N.
Marthan, R.
Berger, P.
Chambellan, A.
Chanez, P.
Aguilaniu, B.
Brillet, P*-Y
Burgel, P*-R
Chaouat, A.
Devillier, P.
Escamilla, R.
LOUIS, Renaud ;  Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
Mal, H.
Muir, J.-F.
Perez, T.
Similowski, T.
Wallaert, B.
Aubier, M.
More authors (8 more) Less
Language :
English
Title :
Beyond corticosteroids: future prospects in the management of inflammation in COPD.
Publication date :
2011
Journal title :
European Respiratory Review
ISSN :
0905-9180
eISSN :
1600-0617
Publisher :
Munksgaard International Publishers, Copenhagen, Denmark
Volume :
20
Issue :
121
Pages :
175-82
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 01 February 2012

Statistics


Number of views
50 (1 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
36
Scopus citations®
without self-citations
36
OpenCitations
 
32

Bibliography


Similar publications



Contact ORBi